Prof Narikazu Boku speaks to ecancer in an online interview for the virtual ESMO 2020 meeting about the ATTRACTION-4 study results.
The study is looking at nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric or gastroesophageal cancer.
Prof Boku reports that the study found nivolumab with chemotherapy achieved improved progression-free survival and overall response rate, although did not result in any significant improvement in overall survival.
Prof Boku also remarks on the real-world nivolumab safety data he presented following on from the ATTRACTION-2 study.
See related news here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.